Effectiveness and Safety of Susvimo (Ranibizumab Port Delivery System) in Diabetic Retinopathy and Diabetic Macular Edema: A Systematic Review and Meta-analysis
Authors:
- 30 May 2026
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1031, 179034
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular EdemaJAMA Ophthalmology, 2025
- Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular EdemaJAMA Ophthalmology, 2025
- Improving Clinical Management of Diabetic Macular Edema: Insights from a Global Survey of Patients, Healthcare Providers, and Clinic StaffOphthalmology and Therapy, 2024
- Clinical Trials and Future Outlooks of the Port Delivery System with Ranibizumab: A Narrative ReviewOphthalmology and Therapy, 2023
- Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2023
- Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USAOphthalmology and Therapy, 2023
- Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications—risks and mitigationEPMA Journal, 2023
- Comprehensive Meta‐Analysis Software2022
- Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessmentsResearch Synthesis Methods, 2020
- Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias toolResearch Synthesis Methods, 2013